Brian Henick
Columbia University · Assistant Professor of Medicine · Assistant Professor of Medicine in the Division of Hematology and Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian Henick as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:46 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06673329 · Brodalumab in the Treatment of Immune-Related Adverse EventsBrian Henick, MD · recruiting · Breast Cancer, Esophageal Cancer, Kidney Cancer · principal investigator
- N/ANCT05812274 · Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC PatientsColumbia University · terminated · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04923776 · Liver Directed RT + Chemo-immunotherapy for ES-SCLCBrian Henick, MD · terminated · Small-cell Lung Cancer · principal investigator
- N/ANCT04791215 · Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With PembrolizumabColumbia University · terminated · Non Small Cell Lung Cancer · principal investigator
- N/ANCT04571398 · A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology TherapyApricity Health, Inc · unknown · Cancer · principal investigator
- Ph2NCT04375228 · Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)Columbia University · active not recruiting · Immune-related Adverse Events, Advanced Solid Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:46 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 210 citationsRCR 12.4
- Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.J Clin Oncol · 2011200 citationsRCR 5.3
- 135 citationsRCR 13.6
- Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.Nat Med · 2025106 citationsRCR 20.7
- 25 citationsRCR 5.0
- Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.JCO Precis Oncol · 202221 citationsRCR 1.2
- Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.J Immunother Cancer · 202410 citationsRCR 0.9
- Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.Eur Radiol · 20237 citationsRCR 0.7